Patents Assigned to Galleon Labs LLC
  • Patent number: 11801261
    Abstract: Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: October 31, 2023
    Assignee: Galleon Labs LLC
    Inventor: Gary S. Hahn
  • Patent number: 11235002
    Abstract: Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: February 1, 2022
    Assignee: Galleon Labs LLC
    Inventors: Gary S. Hahn, Siva Gudi
  • Patent number: 10874689
    Abstract: Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 29, 2020
    Assignee: Galleon Labs LLC
    Inventor: Gary S. Hahn
  • Patent number: 10159693
    Abstract: Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: December 25, 2018
    Assignee: Galleon Labs LLC
    Inventor: Gary S. Hahn